Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004028 · ClinicalTrials.gov registry record · Phase 2
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
A Phase 2 study, sponsored by Verastem.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02004028 is a Phase 2 study that was terminated before completion, run by Verastem. The registered enrollment target is 35 participants.
The verdict
NCT02004028, a Phase 2 study, was terminated before completion, sponsored by Verastem.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery) study in subjects with malignant pleural mesothelioma who are eligible for surgery. Subjects will receive VS-6063 (defactinib) 400 mg twice daily for 12, 21, or 35 days or 100 mg formulation twice daily for 21 days. Pre- and post-treatment biopsies and blood samples will be collected. The purpose of this study is to assess biomarker responses from tumor tissue. The safety, pharmacokinetics, and tumor response rate to VS-6063 (defactinib) will be also be assessed.
Interventions
- DRUG VS-6063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-12-12 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02004028
The ClinicalTrials.gov registry entry for NCT02004028 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VS-6063 is the first listed.
NCT02004028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02004028 about?
NCT02004028 is a clinical study titled "Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants". This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery) study in subjects with malignant pleural mesothelioma who are eligible for surgery. Subjects will receive VS-6063 (defactinib) 400 mg twice daily for 12, 21, or 35 days or 100 mg formulation twice daily for 21 d...
What is the current status of trial NCT02004028?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2013-12-12. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT02004028?
The interventions under investigation include: VS-6063 (DRUG).
Who is sponsoring clinical trial NCT02004028?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.